Marketing authorisations for unmet medical needs: a critical appraisal of regulatory pathways in the European Union.

[1]  E. Sloan,et al.  Drug repurposing using real-world data. , 2022, Drug discovery today.

[2]  T. Kühler,et al.  COVID-19 made the impossible possible - Rolling Reviews from a notion to reality – the EU experience put into a global context , 2022, Clinical Therapeutics.

[3]  Robin L. Jones,et al.  Effect of Doxorubicin Plus Olaratumab vs Doxorubicin Plus Placebo on Survival in Patients With Advanced Soft Tissue Sarcomas: The ANNOUNCE Randomized Clinical Trial. , 2020, JAMA.

[4]  M. Drummond,et al.  Real-World Evidence in Healthcare Decision Making: Global Trends and Case Studies From Latin America. , 2019, Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research.

[5]  L. Mantovani,et al.  Role of healthcare databases and registries for surveillance of orphan drugs in the real-world setting: the Italian case study , 2019, Expert opinion on drug safety.

[6]  Rafal Dziadziuszko,et al.  Alectinib versus Crizotinib in Untreated ALK‐Positive Non–Small‐Cell Lung Cancer , 2017, The New England journal of medicine.

[7]  H. Goldschmidt,et al.  Daratumumab, Lenalidomide, and Dexamethasone for Multiple Myeloma. , 2016, The New England journal of medicine.

[8]  A. Palumbo,et al.  Daratumumab, Bortezomib, and Dexamethasone for Multiple Myeloma. , 2016, The New England journal of medicine.

[9]  M. Feldman,et al.  Stopping Trials Early for Benefit—Not So Fast! , 2012, The Annals of pharmacotherapy.

[10]  Andrew Rhodes,et al.  Drotrecogin alfa (activated) in adults with septic shock. , 2012, The New England journal of medicine.